Background: Women with primary operable breast cancer and at least one positive axillary node, underwent surgery and received following adjuvant treatment in 2-5 wks after the surgery.

Arm A: doxorubicin and cyclophosphamide (AC) 60/600 q 21 d for 4 cycles.
Arm B: doxorubicin and cyclophosphamide (AC) 60/600 q 21 d for 4 cycles, 6mo later received CMF 750/40/600 q 28 days for 3 cycles
Arm C: conventional (at that time) CMF for 6 cycles (Cylophosphomide:100 d1to14, q28d, Methotrexate 400d1 and d8 q28d, and 5-FU 600 d1 and d8 q28 days for 6 cycels.

mFollow up: 3yr

No significant difference in DFS (P=.5), DDFS (P=.5), or OS (P=.8) with less toxicities.

AC was completed on day 63 vs CMF on day 154, patient visit doctors 3 times less with AC, nausea control meds were given for 12 d in AC and for 84 days in CMF group.

Conclusions: This study established AC as a backbone of adjuvant chemotherapy regiment in node positive localized breast cancer. 

Summarized by Veli Bakalov, MD

Send a feedback